P PRIMESTOCKFINDER.COM

UTHR Stock United Therapeutics Corporation

US · NasdaqGS
$588.03 +0.09% Prices as of close 2026-10-26

Last in our picks 2026-10-22 — not in the current list; analysis below is from that screen

Specialty biopharma growth and durable pulmonary franchise support attractive risk-adjusted upside.

Future value: $656.93 (+16.58%) · 6-12 months · analyst consensus

Signal breakdown

  • ▸UBS reiterated Buy with a higher target and positive consensus.
  • ▸Above 50-day MA (+9.16%)
  • ▸Above 200-day MA — long-term uptrend
  • ▸Near 52-week high (77.1% of range) — strength

Is UTHR a buy right now?

Trend: UTHR is trading above the 50-day average (+12.83%), RSI 61 — neutral momentum, with a 3-month return of +12.30%.

Valuation & quality: United Therapeutics Corporation trades on a trailing P/E of 21.1, forward P/E 19.3, PEG 2.22, price-to-book 3.92; fundamentals show net margin 41.6%, return on equity 19.3%, revenue growth -1.9% year on year.

Analyst consensus: 14 analysts have a mean 12-month price target of $661.29 (+12.5% vs the last close; range $368.00 – $728.00), consensus rating “buy”.

Our screen: STRONG BUY (score 4) — Specialty biopharma growth and durable pulmonary franchise support attractive risk-adjusted upside.

Computed from end-of-day data; not personal advice.

12-month price chart

596.8 472.2 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-09 → 2026-10-26 (USD). Range 472.2 – 596.8.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
+17.70%-3.60%-2.50%-2.70%-4.50%-1.40%+6.20%+8.50%

Fundamentals

Market cap
$25.22B
P/E (ttm)
21.1
Forward P/E
19.3
EPS (ttm)
$27.92
Price / book
3.92
PEG
2.22
Beta
0.49
Net margin
41.6%
ROE
19.3%
Revenue growth
-1.9%
Earnings growth
13.4%
Revenue (ttm)
$3.15B
Free cash flow
$557.1M
52-wk range
$409.07 – $609.35
Volume
262,750
Avg volume (3m)
718,856

Analyst price target

Mean target
$661.29
Low
$368.00
High
$728.00
Analysts
14
Consensus
BUY

Technical signals

RSI (14)
61.0
vs 50-day MA
+12.83%
1-mo return
+23.68%
3-mo return
+12.30%
Volume z-score
-0.72

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 1,400 employees · Website

Related Health Care picks

BMRNBioMarin PharmaceuticaIONSIonis Pharmaceuticals,BSXBoston Scientific CorpSYKStryker CorporationUNHUnitedHealth Group IncHUMHumana Inc.BMYBristol-Myers Squibb CHNGEHinge Health, Inc.

Browse: all US stocks · Health Care picks · today's movers

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.